Research Article| Volume 25, ISSUE 1, P39-47, November 1986

Influence of type IIa, IIb and IV-hyper-lipoproteinemia on platelet prostaglandin sensitivity, plasma thromboxane B2 and platelet half-life

      This paper is only available as a PDF. To read, Please Download here.


      It is generally accepted that in hyperlipoproteinemia (HLP) the vascular prostacyclin formation is diminished. We wondered, whether HLP is also associated with changes in platelet sensitivity to antiaggregatory prostaglandins. Therefore, we examined the platelet sensitivity to the prostaglandins PGI2 and PGD2, as well as plasma thromboxane B2 (TXB2)-levels in 24 patients with HLP type IIa, IIb and IV. We found a marked decrease of platelet sensitivity to PGI2 in all the patients examined, which was more pronounced in type IIb than in types Ha and IV. Platelet sensitivity to PGD2 showed no difference in the hyperlipemic patients. Plasma TXB2-levels were significantly increased in comparison to a control group, the changes being most pronounced in patients with type IV HLP. Platelet half-life was significantly shortened in the HLP-patients. This in-vivo platelet function parameter was found to be reduced in patients with type IIa HLP to the greatest extent.
      Our findings suggest that platelet deposition in HLP is promoted not only by diminished vascular PGI2-formation, but also by decreased sensitivity of the platelets to antiaggregatory prostaglandins. The high TXB2-levels and the shortened platelet half-life reflect the in-vivo activated platelet population in these patients.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Prostaglandins, Leukotrienes and Essential Fatty Acids
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Dembinska-Kiec A.
        • Gryglewska T.
        • Zmuda A.
        • Gryglewski J.R.
        The generation of prostacyclin by arteries and by the coronary vascular bed is reduced in experimental atherosclerosis in rabbit.
        Prostaglandins. 1977; 14: 1025-1034
        • Paoletti R.
        • Tremoli E.
        Prostaglandins, thrombin receptors and platelet aggregation in normal and hypercholesterolemic subjects.
        in: Gotto A.M. Smith Louis C. Allen B. Atherosclerosis. V. Springer Verlag, New York, Heidelberg, Berlin1980: 772
        • Tremoli E.
        • Maderna P.
        • Colli S.
        Enhanced platelet aggregation and arachidonic acid metabolism associated to reduced sensitivity to exogenous prostacyclin in hypercholesterolemic subjects.
        Thromb. Haemostas. 1981; 46 (Abstr.): 427
        • Nordøy A.
        • Svensson B.
        • Wiebe D.
        • Hoak J.C.
        Lipoproteins and the inhibitory effect of human endothelial cells on platelet function.
        Circ. Res. 1978; 43: 527-534
      1. Kaliman J, Sinzinger H, Kefalides A, Pachinger O, Probst P. Decreased platelet sensitivity to antiaggregatory prostaglandins in coronary heart disease and angina pectoris-a pathogenetic explanation of the disease? (in press)

        • Sinzinger H.
        • Schernthaner G.
        • Kaliman J.
        Sensitivity of platelets to prostaglandins in coronary heart disease and angina pectoris.
        Prostaglandins. 1981; 22: 773
        • Sinzinger H.
        • Kaliman J.
        • Widhalm K.
        • Pachinger O.
        • Probst P.
        Value of platelet sensitivity to antiaggregatory prostaglandins (PGI2, PGE2, PGD2) in 50 patients with myocardial infarction at young age.
        Prostaglandins and Med. 1981; 7: 125
        • Klein K.
        • Kaliman J.
        • Sinzinger H.
        • Silberbauer K.
        Plättchensensitivität für Prostacyclin bei diabetischen and nicht-diabetischen Patienten mit atherosklerotischen Gefäßveränderungen - ein Maß für die Prostaglandinrezeptoren der Plättchenmembran?.
        VASA. 1980; 9: 123
        • Röschlau B.
        • Bernd E.
        • Gruber W.
        Enzymatische Bestimmung des Gesamtcholesterins im Serum.
        Z. Klin. Chem. Klin. Biochem. 1974; 12: 403
        • Buculo G.
        • David H.
        Quantitative determination of serum triglycerides by the use of enzymes.
        Clin. Chem. 1973; 19: 476
      2. Manual of Labaratory Operations. Lipid Research Clinics Programm. Vol 1, Lipid and Lipoprotein Analysis. NHLI, NIH, Bethesda, Md1974: 75 (DHEW Publ. No. (NIH))
        • Beaumont J.
        • Carlson L.A.
        • Cooper G.R.
        • Fejfar Z.
        • Fredrickson D.S.
        • Strasser T.
        Classification of lipidemias and hyperlipoproteinemias.
        Bull. WHO. 1971; 43: 891
        • Silberbauer K.
        • Schernthaner G.
        • Sinzinger H.
        Einfluß von Plättchenproteinen and Plasmafaktoren auf die PGI2-Synthese.
        in: Deutsch E. Lechner K. Fibrinolyse, Thrombose, Hämostase. F. K. Schattauer, Stuttgart, New York1980: 607-610
        • Anhut H.
        • Bernauer W.
        • Peskar B.A.
        Radioimmunological determination of thromboxane release in cardiac anaphylaxis.
        Europ. J. Pharmacology. 1977; 44: 85
        • Granstrom E.
        Sources of error in prostaglandin and thromboxane radioimmunoassay.
        in: Radioimmunoassay of drugs and hormones in cardiovascular medicine. 1979: 229
        • Du Heyns A.P.
        • Badenhorst P.N.
        • Pieters H.
        • Lötter M.M.G.
        • Minnaar P.C.
        • Duyvene de Wit L.J.
        • Van Reenen O.R.
        • Retief E.P.
        Preparation of a viable population of indium 111-labelled human blood platelets.
        Thromb. Haemost. 1980; 42: 1473
        • Thakur M.
        • Welch M.J.
        • Joist J.H.
        • Coleman R.E.
        Indium-111-labelled platelets. studies on preparation and evaluation of in vitro and in vivo functions.
        Thromb. Res. 1976; 9: 345
        • Sinzinger H.
        • Angelberger P.
        • Kolbe H.
        Influence of incubation time and temperature of in-111-oxine-uptake by human platelets.
        Thromb. Haemost. 1981; 45: 295
        • Lening J.Y.
        • Dykes J.
        • Goldmann M.
        • Hawker R.J.
        • Mc Collen N.
        How should platelet surival be measured?.
        Thromb. Haemost. 1983; 50: 217
        • Strobl W.
        • Widhalm K.
        • Kostner G.
        • Pollak A.
        Serum apolipoproteins and lipoprotein (a) during the first week of life.
        Acta Pediatr. Scand. 1983; 72: 505
        • Stuart M.J.
        • Gerrard J.M.
        • White J.G.
        Effect of cholesterol on production of TXB2 by platelets.
        New Engl. J. Med. 1980; 302: 6
        • Ross R.
        • Harker L.A.
        Hyperlipidemia and atherosclerosis. Chronic hyperlipidemia initiates and maintains lesions by endothelial cell desquamation and lipid accumulation.
        Science. 1976; 193: 1094
        • Kolbe H.
        • Sinzinger H.
        • Widhalm K.
        • Jäger Eva
        • Strobl W.
        Thrombozytenhalbwertszeit bei Patienten mit primarer Hyperlipoproteinämie vor and nach einer dietätischen Behandlung.
        in: van de Loo J. Asbeck F. Hämostase, Thrombophilie and Arteriosklerose. Kongreß für Thrombose and Hämostase Münster. Schattauerverlag, 1982: 402 (Berichtsband 2)
        • D'Angelo V.
        • Villa S.
        • Mysliwiec M.
        • Donati B.
        • De Gaetano G.
        Defective fibrinolytic and prostacyclinlike activity in human atheromatous plaques.
        Thromb. Haemost. 1978; 39: 535
        • Sinzinger H.
        • Silberbauer K.
        • Feigl W.
        Diminished prostacyclin formation by human atherosclerotic arteries.
        Lancet. 1979; i: 469
        • Gryglewski J.R.
        • Dembinska-Kiec S.
        • Zmuda A.
        • Gryglewska T.
        Prostacyclin and thromboxane A2 biosynthesis capacities of the heart arteries and platelets at various stages of experimental atherosclerosis in rabbits.
        Atherosclerosis. 1978; 31: 358
      3. Silberbauer K, Sinzinger H. Unpublished data.